Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 356

1.

Human consciousness is supported by dynamic complex patterns of brain signal coordination.

Demertzi A, Tagliazucchi E, Dehaene S, Deco G, Barttfeld P, Raimondo F, Martial C, Fernández-Espejo D, Rohaut B, Voss HU, Schiff ND, Owen AM, Laureys S, Naccache L, Sitt JD.

Sci Adv. 2019 Feb 6;5(2):eaat7603. doi: 10.1126/sciadv.aat7603. eCollection 2019 Feb.

2.

Immune off-target effects of Brentuximab Vedotin in relapsed/refractory Hodgkin Lymphoma.

Romano A, Parrinello NL, Chiarenza A, Motta G, Tibullo D, Giallongo C, La Cava P, Camiolo G, Puglisi F, Palumbo GA, Di Raimondo F.

Br J Haematol. 2019 Feb 15. doi: 10.1111/bjh.15801. [Epub ahead of print]

PMID:
30768678
3.

Once-weekly versus twice-weekly carfilzomib in patients with newly diagnosed multiple myeloma: a pooled analysis of two phase 1/2 studies.

Bringhen S, Mina R, Petrucci MT, Gaidano G, Ballanti S, Musto P, Offidani M, Spada S, Benevolo G, Ponticelli E, Galieni P, Cavo M, Caravita di Toritto T, Di Raimondo F, Montefusco V, Palumbo A, Boccadoro M, Larocca A.

Haematologica. 2019 Feb 7. pii: haematol.2018.208272. doi: 10.3324/haematol.2018.208272. [Epub ahead of print]

4.

α-Lipoic Acid Reduces Iron-induced Toxicity and Oxidative Stress in a Model of Iron Overload.

Camiolo G, Tibullo D, Giallongo C, Romano A, Parrinello NL, Musumeci G, Di Rosa M, Vicario N, Brundo MV, Amenta F, Ferrante M, Copat C, Avola R, Li Volti G, Salvaggio A, Di Raimondo F, Palumbo GA.

Int J Mol Sci. 2019 Jan 31;20(3). pii: E609. doi: 10.3390/ijms20030609.

5.

Management of infectious complications in multiple myeloma patients: Expert panel consensus-based recommendations.

Girmenia C, Cavo M, Offidani M, Scaglione F, Corso A, Di Raimondo F, Musto P, Petrucci MT, Barosi G.

Blood Rev. 2019 Mar;34:84-94. doi: 10.1016/j.blre.2019.01.001. Epub 2019 Jan 9. Review.

PMID:
30683446
6.

Successful coronary artery bypass graft surgery in severe congenital factor VII deficiency: Perioperative treatment with pd-factor VII concentrate.

Giuffrida G, Nicolosi D, Giuffrida A, Rapisarda C, Calafiore V, Giuffrida A, Di Raimondo F.

Haemophilia. 2018 Dec 27. doi: 10.1111/hae.13657. [Epub ahead of print] No abstract available.

PMID:
30589157
7.

Differences in presenting features, outcome and prognostic models in patients with primary myelofibrosis and post-polycythemia vera and/or post-essential thrombocythemia myelofibrosis treated with ruxolitinib. New perspective of the MYSEC-PM in a large multicenter study.

Palandri F, Palumbo GA, Iurlo A, Polverelli N, Benevolo G, Breccia M, Abruzzese E, Tiribelli M, Bonifacio M, Tieghi A, Isidori A, Martino B, Sgherza N, D'Adda M, Bergamaschi M, Crugnola M, Cavazzini F, Bosi C, Binotto G, Auteri G, Latagliata R, Ibatici A, Scaffidi L, Penna D, Cattaneo D, Soci F, Trawinska M, Russo D, Cuneo A, Semenzato G, Di Raimondo F, Aversa F, Lemoli RM, Heidel F, Reggiani MLB, Bartoletti D, Cavo M, Catani L, Vianelli N.

Semin Hematol. 2018 Oct;55(4):248-255. doi: 10.1053/j.seminhematol.2018.05.013. Epub 2018 Jun 5.

PMID:
30502854
8.

Electrophysiological approaches in the study of cognitive development outside the lab.

Pietto ML, Gatti M, Raimondo F, Lipina SJ, Kamienkowski JE.

PLoS One. 2018 Nov 26;13(11):e0206983. doi: 10.1371/journal.pone.0206983. eCollection 2018.

9.

Long-Term Molecular Remission Achieved by Antibody Anti-CD22 and Ponatinib in a Patient Affected by Ph'+ Acute Lymphoblastic Leukemia Relapsed after Second Allogeneic Hematopoietic Stem Cell Transplantation: A Case Report.

Pirosa MC, Leotta S, Cupri A, Stella S, Martino EA, Scalise L, Sapienza G, Calafiore V, Mauro E, Spadaro A, Vigneri P, Di Raimondo F, Milone G.

Chemotherapy. 2018;63(4):220-224. doi: 10.1159/000492941. Epub 2018 Oct 29.

PMID:
30372691
10.

Is re-challenge still an option as salvage therapy in multiple myeloma? The case of REal-life BOrtezomib re-Use as secoND treatment for relapsed patients exposed frontline to bortezomib-based therapies (the REBOUND Study).

Musto P, Simeon V, Cascavilla N, Falcone A, Petrucci MT, Cesini L, Di Raimondo F, Conticello C, Ria R, Catalano L, Salvatore D, Mastrullo L, Gagliardi A, Villani O, Pietrantuono G, D'Arena G, Mansueto G, Bringhen S, Genuardi M, Di Renzo N, Reddiconto G, Fragasso A, Caravita T, Scapicchio D, Marziano G, Boccadoro M, Mangiacavalli S, Corso A.

Ann Hematol. 2019 Feb;98(2):361-367. doi: 10.1007/s00277-018-3524-1. Epub 2018 Oct 23.

PMID:
30353388
11.

Robust EEG-based cross-site and cross-protocol classification of states of consciousness.

Engemann DA, Raimondo F, King JR, Rohaut B, Louppe G, Faugeras F, Annen J, Cassol H, Gosseries O, Fernandez-Slezak D, Laureys S, Naccache L, Dehaene S, Sitt JD.

Brain. 2018 Nov 1;141(11):3179-3192. doi: 10.1093/brain/awy251.

PMID:
30285102
12.

Targeting heme Oxygenase-1 with hybrid compounds to overcome Imatinib resistance in chronic myeloid leukemia cell lines.

Sorrenti V, Pittalà V, Romeo G, Amata E, Dichiara M, Marrazzo A, Turnaturi R, Prezzavento O, Barbagallo I, Vanella L, Rescifina A, Floresta G, Tibullo D, Di Raimondo F, Intagliata S, Salerno L.

Eur J Med Chem. 2018 Oct 5;158:937-950. doi: 10.1016/j.ejmech.2018.09.048. Epub 2018 Sep 17.

PMID:
30261468
13.

Maintenance Treatment and Survival in Patients With Myeloma: A Systematic Review and Network Meta-analysis.

Gay F, Jackson G, Rosiñol L, Holstein SA, Moreau P, Spada S, Davies F, Lahuerta JJ, Leleu X, Bringhen S, Evangelista A, Hulin C, Panzani U, Cairns DA, Di Raimondo F, Macro M, Liberati AM, Pawlyn C, Offidani M, Spencer A, Hájek R, Terpos E, Morgan GJ, Bladé J, Sonneveld P, San-Miguel J, McCarthy PL, Ludwig H, Boccadoro M, Mateos MV, Attal M.

JAMA Oncol. 2018 Oct 1;4(10):1389-1397. doi: 10.1001/jamaoncol.2018.2961.

PMID:
30098165
14.

Predictive value of the CLL-IPI in CLL patients receiving chemo-immunotherapy as first-line treatment.

Gentile M, Shanafelt TD, Mauro FR, Reda G, Rossi D, Laurenti L, Del Principe MI, Cutrona G, Angeletti I, Coscia M, Herishanu Y, Chiarenza A, Molica S, Ciolli S, Goldschmidt N, Angrilli F, Giordano A, Rago A, Bairey O, Tripepi G, Chaffee KG, Sameer PA, Vigna E, Zirlik K, Shvidel L, Innocenti I, Recchia AG, Di Raimondo F, Del Poeta G, Cortelezzi A, Neri A, Ferrarini M, Gaidano G, Kay NE, Polliack A, Foà R, Morabito F.

Eur J Haematol. 2018 Jul 24. doi: 10.1111/ejh.13149. [Epub ahead of print] No abstract available.

PMID:
30039576
15.

Immunoglobulin heavy chain variable region gene and prediction of time to first treatment in patients with chronic lymphocytic leukemia: Mutational load or mutational status? Analysis of 1003 cases.

Morabito F, Shanafelt TD, Gentile M, Reda G, Mauro FR, Rossi D, Di Renzo N, Molica S, Angrilli F, Chiarenza A, Cutrona G, Chaffee KG, Parikh SA, Tripepi G, D'Arrigo G, Vigna E, Recchia AG, Cortelezzi A, Gaidano G, Di Raimondo F, Fais F, Foà R, Neri A, Ferrarini M.

Am J Hematol. 2018 Sep;93(9):E216-E219. doi: 10.1002/ajh.25206. Epub 2018 Jul 30. No abstract available.

PMID:
29984867
16.

Evolution of Nanoparticle Protein Corona across the Blood-Brain Barrier.

Cox A, Andreozzi P, Dal Magro R, Fiordaliso F, Corbelli A, Talamini L, Chinello C, Raimondo F, Magni F, Tringali M, Krol S, Jacob Silva P, Stellacci F, Masserini M, Re F.

ACS Nano. 2018 Jul 24;12(7):7292-7300. doi: 10.1021/acsnano.8b03500. Epub 2018 Jul 2.

PMID:
29953205
17.

Heme Oxygenase Inhibition Sensitizes Neuroblastoma Cells to Carfilzomib.

Barbagallo I, Giallongo C, Volti GL, Distefano A, Camiolo G, Raffaele M, Salerno L, Pittalà V, Sorrenti V, Avola R, Di Rosa M, Vanella L, Di Raimondo F, Tibullo D.

Mol Neurobiol. 2018 Jun 10. doi: 10.1007/s12035-018-1133-6. [Epub ahead of print]

PMID:
29948946
18.

Effects of Hematuria on the Proteomic Profile of Urinary Extracellular Vesicles: Technical Challenges.

Raimondo F, Chinello C, Stella M, Santorelli L, Magni F, Pitto M.

J Proteome Res. 2018 Aug 3;17(8):2572-2580. doi: 10.1021/acs.jproteome.7b00763. Epub 2018 Jun 28.

PMID:
29905074
19.

PMN-MDSC and arginase are increased in myeloma and may contribute to resistance to therapy.

Romano A, Parrinello NL, La Cava P, Tibullo D, Giallongo C, Camiolo G, Puglisi F, Parisi M, Pirosa MC, Martino E, Conticello C, Palumbo GA, Di Raimondo F.

Expert Rev Mol Diagn. 2018 Jul;18(7):675-683. doi: 10.1080/14737159.2018.1470929. Epub 2018 May 3.

PMID:
29707981
20.

Maintenance in myeloma patients achieving complete response after upfront therapy: a pooled analysis.

Cerrato C, Di Raimondo F, De Paoli L, Spada S, Patriarca F, Crippa C, Mina R, Guglielmelli T, Ben-Yehuda D, Oddolo D, Nozzoli C, Angelucci E, Cascavilla N, Rizzi R, Rocco S, Baldini L, Ponticelli E, Marcatti M, Cangialosi C, Caravita T, Benevolo G, Ria R, Nagler A, Musto P, Tacchetti P, Corradini P, Offidani M, Palumbo A, Petrucci MT, Boccadoro M, Gay F.

J Cancer Res Clin Oncol. 2018 Jul;144(7):1357-1366. doi: 10.1007/s00432-018-2641-5. Epub 2018 Apr 19.

PMID:
29675792
21.

Validation of a biological score to predict response in chronic lymphocytic leukemia patients treated front-line with bendamustine and rituximab.

Gentile M, Shanafelt TD, Reda G, Mauro FR, Zirlik K, Ciolli S, Laurenti L, Del Principe MI, Rossi D, Di Renzo N, Molica S, Angrilli F, Coscia M, Chiarenza A, Giordano A, Cutrona G, Chaffee KG, Parikh SA, Uccello G, Innocenti I, Tripepi G, D'Arrigo G, Vigna E, Recchia AG, Herishanu Y, Shvidel L, Tadmor T, Cortelezzi A, Del Poeta G, Gaidano G, Di Raimondo F, Neri A, Ferrarini M, Foà R, Polliack A, Morabito F.

Leukemia. 2018 Aug;32(8):1869-1873. doi: 10.1038/s41375-018-0100-6. Epub 2018 Mar 20. No abstract available.

PMID:
29588545
22.

Non ABL-directed inhibitors as alternative treatment strategies for chronic myeloid leukemia.

Massimino M, Stella S, Tirrò E, Romano C, Pennisi MS, Puma A, Manzella L, Zanghì A, Stagno F, Di Raimondo F, Vigneri P.

Mol Cancer. 2018 Feb 19;17(1):56. doi: 10.1186/s12943-018-0805-1. Review.

23.

Prognostic meaning of neutrophil to lymphocyte ratio (NLR) and lymphocyte to monocyte ration (LMR) in newly diagnosed Hodgkin lymphoma patients treated upfront with a PET-2 based strategy.

Romano A, Parrinello NL, Vetro C, Chiarenza A, Cerchione C, Ippolito M, Palumbo GA, Di Raimondo F.

Ann Hematol. 2018 Jun;97(6):1009-1018. doi: 10.1007/s00277-018-3276-y. Epub 2018 Feb 14.

PMID:
29442162
24.

Essential oil of Citrus lumia Risso: Phytochemical profile, antioxidant properties and activity on the central nervous system.

Smeriglio A, Alloisio S, Raimondo FM, Denaro M, Xiao J, Cornara L, Trombetta D.

Food Chem Toxicol. 2018 Sep;119:407-416. doi: 10.1016/j.fct.2017.12.053. Epub 2017 Dec 28.

PMID:
29288755
25.

The NLR and LMR ratio in newly diagnosed MM patients treated upfront with novel agents.

Romano A, Laura Parrinello N, Cerchione C, Letizia Consoli M, Parisi M, Calafiore V, Martino E, Conticello C, Di Raimondo F, Alberto Palumbo G.

Blood Cancer J. 2017 Dec 15;7(12):649. doi: 10.1038/s41408-017-0019-6. No abstract available.

26.

Monocytic myeloid-derived suppressor cells as prognostic factor in chronic myeloid leukaemia patients treated with dasatinib.

Giallongo C, Parrinello NL, La Cava P, Camiolo G, Romano A, Scalia M, Stagno F, Palumbo GA, Avola R, Li Volti G, Tibullo D, Di Raimondo F.

J Cell Mol Med. 2018 Feb;22(2):1070-1080. doi: 10.1111/jcmm.13326. Epub 2017 Dec 8.

27.

Survival and consciousness recovery are better in the minimally conscious state than in the vegetative state.

Faugeras F, Rohaut B, Valente M, Sitt J, Demeret S, Bolgert F, Weiss N, Grinea A, Marois C, Quirins M, Demertzi A, Raimondo F, Galanaud D, Habert MO, Engemann D, Puybasset L, Naccache L.

Brain Inj. 2018;32(1):72-77. doi: 10.1080/02699052.2017.1364421. Epub 2017 Nov 20.

28.

Baseline factors associated with response to ruxolitinib: an independent study on 408 patients with myelofibrosis.

Palandri F, Palumbo GA, Bonifacio M, Tiribelli M, Benevolo G, Martino B, Abruzzese E, D'Adda M, Polverelli N, Bergamaschi M, Tieghi A, Cavazzini F, Ibatici A, Crugnola M, Bosi C, Latagliata R, Di Veroli A, Scaffidi L, de Marchi F, Cerqui E, Anaclerico B, De Matteis G, Spinsanti M, Sabattini E, Catani L, Aversa F, Di Raimondo F, Vitolo U, Lemoli RM, Fanin R, Merli F, Russo D, Cuneo A, Bacchi Reggiani ML, Cavo M, Vianelli N, Breccia M.

Oncotarget. 2017 Jun 27;8(45):79073-79086. doi: 10.18632/oncotarget.18674. eCollection 2017 Oct 3.

29.

Effects of prolonged drought on stem non-structural carbohydrates content and post-drought hydraulic recovery in Laurus nobilis L.: The possible link between carbon starvation and hydraulic failure.

Trifilò P, Casolo V, Raimondo F, Petrussa E, Boscutti F, Lo Gullo MA, Nardini A.

Plant Physiol Biochem. 2017 Nov;120:232-241. doi: 10.1016/j.plaphy.2017.10.003. Epub 2017 Oct 12.

PMID:
29073538
30.

Low-dose lenalidomide plus cytarabine in very elderly, unfit acute myeloid leukemia patients: Final result of a phase II study.

Visani G, Ferrara F, Di Raimondo F, Loscocco F, Fuligni F, Paolini S, Zammit V, Spina E, Rocchi M, Visani A, Piccaluga PP, Isidori A.

Leuk Res. 2017 Nov;62:77-83. doi: 10.1016/j.leukres.2017.09.019. Epub 2017 Sep 25.

31.

NOTCH1 mutations are associated with high CD49d expression in chronic lymphocytic leukemia: link between the NOTCH1 and the NF-κB pathways.

Benedetti D, Tissino E, Pozzo F, Bittolo T, Caldana C, Perini C, Martorelli D, Bravin V, D'Agaro T, Rossi FM, Bomben R, Santinelli E, Zaja F, Pozzato G, Chiarenza A, Di Raimondo F, Del Poeta G, Rossi D, Gaidano G, Dal Bo M, Gattei V, Zucchetto A.

Leukemia. 2018 Mar;32(3):654-662. doi: 10.1038/leu.2017.296. Epub 2017 Sep 22.

PMID:
28935990
32.

High BCR-ABL/GUSIS Levels at Diagnosis of Chronic Phase CML Are Associated with Unfavorable Responses to Standard-Dose Imatinib.

Vigneri P, Stagno F, Stella S, Cupri A, Forte S, Massimino M, Antolino A, Siragusa S, Mannina D, Impera SS, Musolino C, Malato A, Mineo G, Tomaselli C, Murgano P, Musso M, Morabito F, Molica S, Martino B, Manzella L, Müller MC, Hochhaus A, Raimondo FD.

Clin Cancer Res. 2017 Dec 1;23(23):7189-7198. doi: 10.1158/1078-0432.CCR-17-0962. Epub 2017 Sep 19.

33.

Brain-heart interactions reveal consciousness in noncommunicating patients.

Raimondo F, Rohaut B, Demertzi A, Valente M, Engemann DA, Salti M, Fernandez Slezak D, Naccache L, Sitt JD.

Ann Neurol. 2017 Oct;82(4):578-591. doi: 10.1002/ana.25045. Epub 2017 Oct 11.

PMID:
28892566
34.

Mutational status of IGHV is the most reliable prognostic marker in trisomy 12 chronic lymphocytic leukemia.

Bulian P, Bomben R, Bo MD, Zucchetto A, Rossi FM, Degan M, Pozzo F, Bittolo T, Bravin V, D'Agaro T, Cerri M, Chiarenza A, Chaffee KG, Condoluci A, D'Arena G, Spina M, Zaja F, Pozzato G, Di Raimondo F, Rossi D, Poeta GD, Gaidano G, Shanafelt TD, Gattei V.

Haematologica. 2017 Nov;102(11):e443-e446. doi: 10.3324/haematol.2017.170340. Epub 2017 Jul 27. No abstract available.

35.

NOTCH1 mutational status in chronic lymphocytic leukaemia: clinical relevance of subclonal mutations and mutation types.

D'Agaro T, Bittolo T, Bravin V, Dal Bo M, Pozzo F, Bulian P, Rossi FM, Zucchetto A, Degan M, D'Arena G, Chiarenza A, Zaja F, Pozzato G, Di Raimondo F, Rossi D, Gaidano G, Del Poeta G, Gattei V, Bomben R.

Br J Haematol. 2018 Aug;182(4):597-602. doi: 10.1111/bjh.14843. Epub 2017 Jul 12. No abstract available.

PMID:
28699643
36.

Probing consciousness in a sensory-disconnected paralyzed patient.

Rohaut B, Raimondo F, Galanaud D, Valente M, Sitt JD, Naccache L.

Brain Inj. 2017;31(10):1398-1403. doi: 10.1080/02699052.2017.1327673. Epub 2017 Jun 28.

PMID:
28657353
37.

Autoreject: Automated artifact rejection for MEG and EEG data.

Jas M, Engemann DA, Bekhti Y, Raimondo F, Gramfort A.

Neuroimage. 2017 Oct 1;159:417-429. doi: 10.1016/j.neuroimage.2017.06.030. Epub 2017 Jun 20.

PMID:
28645840
38.

Mutations in the 3' untranslated region of NOTCH1 are associated with low CD20 expression levels chronic lymphocytic leukemia.

Bittolo T, Pozzo F, Bomben R, D'Agaro T, Bravin V, Bulian P, Rossi FM, Zucchetto A, Degan M, Macor P, D'Arena G, Chiarenza A, Zaja F, Pozzato G, Di Raimondo F, Rossi D, Gaidano G, Del Poeta G, Gattei V, Dal Bo M.

Haematologica. 2017 Aug;102(8):e305-e309. doi: 10.3324/haematol.2016.162594. Epub 2017 May 26. No abstract available.

39.

Proteomic Analysis Reveals Autophagy as Pro-Survival Pathway Elicited by Long-Term Exposure with 5-Azacitidine in High-Risk Myelodysplasia.

Romano A, Giallongo C, La Cava P, Parrinello NL, Chiechi A, Vetro C, Tibullo D, Di Raimondo F, Liotta LA, Espina V, Palumbo GA.

Front Pharmacol. 2017 Apr 26;8:204. doi: 10.3389/fphar.2017.00204. eCollection 2017.

40.

NOTCH1-mutated chronic lymphocytic leukemia cells are characterized by a MYC-related overexpression of nucleophosmin 1 and ribosome-associated components.

Pozzo F, Bittolo T, Vendramini E, Bomben R, Bulian P, Rossi FM, Zucchetto A, Tissino E, Degan M, D'Arena G, Di Raimondo F, Zaja F, Pozzato G, Rossi D, Gaidano G, Del Poeta G, Gattei V, Dal Bo M.

Leukemia. 2017 Nov;31(11):2407-2415. doi: 10.1038/leu.2017.90. Epub 2017 Mar 21.

PMID:
28321119
41.

Chemical composition and antimicrobial activity of the essential oils of some species of Anthemis sect. Anthemis (Asteraceae) from Sicily.

Riccobono L, Maggio A, Bruno M, Spadaro V, Raimondo FM.

Nat Prod Res. 2017 Dec;31(23):2759-2767. doi: 10.1080/14786419.2017.1297444. Epub 2017 Mar 3.

PMID:
28278620
42.

The Heme Oxygenase System in Hematological Malignancies.

Li Volti G, Tibullo D, Vanella L, Giallongo C, Di Raimondo F, Forte S, Di Rosa M, Signorelli SS, Barbagallo I.

Antioxid Redox Signal. 2017 Aug 20;27(6):363-377. doi: 10.1089/ars.2016.6735. Epub 2017 May 19. Review.

PMID:
28257621
43.

Randomized Trial Comparing R-CHOP Versus High-Dose Sequential Chemotherapy in High-Risk Patients With Diffuse Large B-Cell Lymphomas.

Cortelazzo S, Tarella C, Gianni AM, Ladetto M, Barbui AM, Rossi A, Gritti G, Corradini P, Di Nicola M, Patti C, Mulé A, Zanni M, Zoli V, Billio A, Piccin A, Negri G, Castellino C, Di Raimondo F, Ferreri AJ, Benedetti F, La Nasa G, Gini G, Trentin L, Frezzato M, Flenghi L, Falorio S, Chilosi M, Bruna R, Tabanelli V, Pileri S, Masciulli A, Delaini F, Boschini C, Rambaldi A.

J Clin Oncol. 2016 Nov 20;34(33):4015-4022. doi: 10.1200/JCO.2016.67.2980. Epub 2016 Oct 31.

44.

Pomalidomide experience: an effective therapeutic approach with immunomodulatory drugs in a patient with relapsed-refractory multiple myeloma.

Conticello C, Parisi M, Romano A, Calafiore V, Ancora F, La Fauci A, Consoli ML, Di Raimondo F.

Future Oncol. 2017 Feb;13(5s):3-6. doi: 10.2217/fon-2016-0368.

PMID:
28116941
45.

Pomalidomide: when expectations are understated.

Di Raimondo F, Conticello C.

Future Oncol. 2017 Feb;13(5s):1-2. doi: 10.2217/fon-2016-0559. No abstract available.

46.

Lenalidomide and low-dose dexamethasone (Rd) versus bortezomib, melphalan, prednisone (VMP) in elderly newly diagnosed multiple myeloma patients: A comparison of two prospective trials.

Gentile M, Magarotto V, Offidani M, Musto P, Bringhen S, Teresa Petrucci M, Gay F, Larocca A, Uccello G, Petrungaro A, Vigna E, Greco R, Grazia Recchia A, Tripepi G, Ria R, Di Raimondo F, Palumbo A, Morabito F.

Am J Hematol. 2017 Mar;92(3):244-250. doi: 10.1002/ajh.24621. Epub 2017 Jan 23.

47.

Childhood neurofibromatosis type 2 (NF2) and related disorders: from bench to bedside and biologically targeted therapies.

Ruggieri M, Praticò AD, Serra A, Maiolino L, Cocuzza S, Di Mauro P, Licciardello L, Milone P, Privitera G, Belfiore G, Di Pietro M, Di Raimondo F, Romano A, Chiarenza A, Muglia M, Polizzi A, Evans DG.

Acta Otorhinolaryngol Ital. 2016 Oct;36(5):345-367. doi: 10.14639/0392-100X-1093. Review.

48.

Successful switch from enzyme replacement therapy to miglustat in an adult patient with type 1 Gaucher disease: a case report.

Giuffrida G, Lombardo R, Di Francesco E, Parrinello L, Di Raimondo F, Fiumara A.

J Med Case Rep. 2016 Nov 8;10(1):315.

49.

The proteomic landscape of renal tumors.

Chinello C, L'imperio V, Stella M, Smith AJ, Bovo G, Grasso A, Grasso M, Raimondo F, Pitto M, Pagni F, Magni F.

Expert Rev Proteomics. 2016 Dec;13(12):1103-1120. Epub 2016 Oct 28. Review.

PMID:
27748142
50.

A population-based study of chronic myeloid leukemia patients treated with imatinib in first line.

Castagnetti F, Di Raimondo F, De Vivo A, Spitaleri A, Gugliotta G, Fabbiano F, Capodanno I, Mannina D, Salvucci M, Antolino A, Marasca R, Musso M, Crugnola M, Impera S, Trabacchi E, Musolino C, Cavazzini F, Mineo G, Tosi P, Tomaselli C, Rizzo M, Siragusa S, Fogli M, Ragionieri R, Zironi A, Soverini S, Martinelli G, Cavo M, Vigneri P, Stagno F, Rosti G, Baccarani M.

Am J Hematol. 2017 Jan;92(1):82-87. doi: 10.1002/ajh.24591. Epub 2016 Nov 18.

Supplemental Content

Loading ...
Support Center